Yahoo Suche Web Suche

Suchergebnisse

1. Suchergebnisse:

1. twitter.com › adrenomedAdrenomed AG (@adrenomed) / Twitter

   twitter.com › adrenomed

   • Im Cache

   16. Nov. 2018 · Adrenomed AG. @adrenomed. An innovative biomarker-guided #precisionmedicine solution for patients in acute care with #sepsis and #septicshock. #enibarcimab. Hennigsdorf, Deutschland adrenomed.com Joined November 2018. 218 Following.

2. adrenomed.comAdrenomed – Adrenomed AG

   adrenomed.com

   • Im Cache

   AdrenoMed AG is a privately-financed, clinical-stage biopharmaceutical company with a clear mission: developing precision medicine to rescue vascular integrity and saving the lives of critically ill patients with limited treatment options. The Company’s lead product candidate is Enibarcimab (INN, former name: Adrecizumab), a clinical-stage ...

3. twitter.com › adrenomed › statusAdrenomed AG on Twitter: "In #November, meet our CEO and CFO at...

   twitter.com › adrenomed › status

   13. Okt. 2022 · In #November, meet our CEO and CFO at: @LSXLeaders’ Inv€$tival #Showcase November 14, 2022, in-person in #London, UK. 13 Oct 2022 07:41:09

4. www.handelsblatt.com › unternehmen › mittelstandAdrenomed: Das ist die nächste Biotech-Hoffnung der Investoren

   www.handelsblatt.com › unternehmen › mittelstand

   19. Okt. 2021 · Andreas Bergmann. Kampf gegen Sepsis – Adrenomed könnte nächste deutsche Biotech-Erfolgsgeschichte werden. Der Biochemiker Andreas Bergmann will den ersten Wirkstoff gegen Sepsis zur Marktreife...

   • Autor: Maike Telgheder

   • Tätigkeit: Redakteurin

5. adrenomed.com › 2024/04/10-adrenomed-fda-fast-track-enibarcimabAdrenoMed Receives FDA Fast Track Designation for Enibarcimab for...

   adrenomed.com › 2024/04/10-adrenomed-fda-fast-track-enibarcimab

   • Im Cache

   10. Apr. 2024 · 10. April 2024. Hennigsdorf/Berlin (Germany), April 10, 2024 –AdrenoMed AG, the vascular integrity company, today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to its lead product candidate enibarcimab, a first-in-class non-neutralizing monoclonal antibody, for the treatment of septic shock.

6. www.nature.com › articles › d43747/021/00098-8The key to treating sepsis and septic shock: matching ... -...

   www.nature.com › articles › d43747/021/00098-8

   • Im Cache

   The key to treating sepsis and septic shock: matching treatment to causal pathophysiology. Adrenomed AG is translating the concept of precision medicine to acute care with a biomarker-guided ...

7. adrenomed.com › 20212021 – Adrenomed

   adrenomed.com › 2021

   • Im Cache

   23. Aug. 2021 · Positive EMA feedback on planned pivotal trial in septic shock Important step forward in global regulatory strategy for Adrecizumab Hennigsdorf/Berlin (Germany), December 2, 2021 – Adrenomed AG, the vascular integrity company, today announced that it. 2. December 2021. Adrenomed will be attending J.P. Morgan 40th Annual Healthcare Conference ...